0 45

Cited 3 times in

Salvage therapy for acute chemorefractory leukemia by allogeneic stem cell transplantation: the Korean experience

 Shin Hye Yoo  ;  Youngil Koh  ;  Dae-Young Kim  ;  Jung-Hee Lee  ;  Je-Hwan Lee  ;  Kyoo-Hyung Lee  ;  Sung-Soo Yoon  ;  Seonyang Park  ;  Sung-Kyu Park  ;  Dae-Sik Hong  ;  Hyeon Gyu Yi  ;  Chul-Soo Kim  ;  Ji Eun Jang  ;  June-Won Cheong  ;  Joonho Moon  ;  Yoo Hong Min  ;  Sang Kyun Sohn  ;  Inho Kim 
 Annals of Hematology, Vol.96(4) : 605-615, 2017 
Journal Title
 Annals of Hematology 
Issue Date
Acute Disease ; Adult ; Female ; Graft vs Host Disease/diagnosis* ; Graft vs Host Disease/mortality ; Graft vs Host Disease/therapy* ; Hematopoietic Stem Cell Transplantation/methods* ; Hematopoietic Stem Cell Transplantation/mortality ; Humans ; Leukemia/diagnosis* ; Leukemia/mortality ; Leukemia/therapy* ; Male ; Middle Aged ; Republic of Korea/epidemiology ; Retrospective Studies ; Salvage Therapy/methods* ; Salvage Therapy/mortality ; Survival Rate/trends ; Transplantation, Homologous
Acute leukemia ; Allogeneic hematopoietic stem cell transplantation ; Chemorefractoriness ; Graft-versus-host disease
Little is known about the characteristics that make patients with acute leukemia suitable for undergoing salvage therapy by allogeneic hematopoietic stem cell transplantation (allo-HSCT). Here, we analyzed the clinical outcomes of 223 patients with acute leukemia who underwent allo-HSCT while not in complete remission (CR). The primary end points were overall survival (OS) and CR rate. CR was achieved in 79.8% of patients after allo-HSCT. Acute graft-versus-host disease (GVHD) was significantly associated with CR (P = 0.045). During a median follow-up of 30.1 months, the median OS was 6.1 months. OS was significantly longer in patients with good or standard risk cytogenetic characteristics than in those with poor risk cytogenetic characteristics (P = 0.029, P = 0.030, respectively). Patients who received allo-HSCT from a matched sibling donor had better survival than those with unrelated donors (P = 0.015). Primary chemorefractoriness was not associated with poor survival (P = 0.071). The number of chemotherapies before allo-HSCT was significantly correlated with outcome (P = 0.006). Chronic GVHD was a strong predictor of a longer OS (P = 0.025). In conclusion, survival of patients with primary chemorefractory acute leukemia is not lower when treated upfront with allo-HSCT. Hence, allo-HSCT should be actively considered in such patients. Acute and chronic GVHD is associated with better outcomes patients with acute leukemia who have undergone allo-HSCT and not achieved CR.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
민유홍(Min, Yoo Hong) ORCID logo https://orcid.org/0000-0001-8542-9583
장지은(Jang, Ji Eun) ORCID logo https://orcid.org/0000-0001-8832-1412
정준원(Cheong, June-Won) ORCID logo https://orcid.org/0000-0002-1744-0921
RIS (EndNote)
XLS (Excel)
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.